Despite the potential of drugs like Eribulin, a non-taxane microtubule inhibitor, in improving survival outcomes for advanced breast cancer patients, there is a dearth of large-scale, real-world evidence specific to Chinese patients with HER2-negative advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.